CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, Francois-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R
Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.